Editorial: Secondary prevention, the interventional way: Prophylactic drug-eluting stents for nonobstructive saphenous vein graft disease

Circulation

Volumn 120, Issue 20, 2009, Pages 1940-1942

  Parikh, Sahil A ^a   Costa, Marco A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUBULIN MODULATOR;

ACUTE CORONARY SYNDROME; ARTERY INTIMA PROLIFERATION; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BARE METAL STENT; CLINICAL ASSESSMENT; DIAGNOSTIC IMAGING; DRUG ELUTING STENT; EDITORIAL; EXERCISE; FOLLOW UP; HEART INFARCTION; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; INTRAVASCULAR ULTRASOUND; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RESTENOSIS; SECONDARY PREVENTION; VEIN GRAFT DISEASE; AGED; BLOOD; CORONARY ARTERY BYPASS GRAFT; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; GRAFT OCCLUSION; MALE; METHODOLOGY; MIDDLE AGED; NOTE; PILOT STUDY; PROSPECTIVE STUDY;

AGED; ATHEROSCLEROSIS; CHOLESTEROL, LDL; CORONARY ARTERY BYPASS; DRUG-ELUTING STENTS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PILOT PROJECTS; PROSPECTIVE STUDIES; TUBULIN MODULATORS;

EID: 72449169658     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.903146     Document Type: Editorial

References (16)

1. Ribichini F, Pugno F, Ferrero V, Wijns W, Vacca G, Vassanelli C, Virmani R. Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts. Clin Sci (Lond). 2008;114: 211-220.
2. Safian RD. Accelerated atherosclerosis in saphenous vein bypass grafts: a spectrum of diffuse plaque instability. Prog Cardiovasc Dis. 2002;44: 437-448.
3. Ellis SG, Brener SJ, DeLuca S, Tuzcu EM, Raymond RE, Whitlow PL, Topol EJ. Late myocardial ischemic events after saphenous vein graft intervention: importance of initially "nonsignificant" vein graft lesions. Am J Cardiol. 1997;79:1460-1464.
4. Rodés-Cabau J, Bertrand OF, Larose E, Déry J-P, Rinfret S, Bagur R, Proulx G, Nguyen CM, Côté M, Landcop M-C, Boudreault J-R, Rouleau J, Roy L, Gleeton O, Barbeau G, Noël B, Courtis J, Dagenais GR, Després J-P, DeLarochellière R. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the Moderate Vein Graft Lesion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) pilot trial. Circulation. 2009;120:1978-1986.
5. Peykar S, Angiolillo DJ, Bass TA. Saphenous vein graft disease. Minerva Cardioangiol. 2004;52:379-390.
6. Goswami NJ, Gaffigan M, Berrio G, Plessa AL, Pfeiffer AM, Markwell SJ, Mishkel GJ. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry. Catheter Cardiovasc Interv. June 23, 2009. DOI: 10.1002/ ccd.22194. Available at: http://www3.interscience.wiley.com/user/ accessdenied?ID = 122463369&Act=2138&Code = 4717&Page=/cgi-bin/ fulltext/122463369/HTMLSTART. Accessed October 1, 2009.
7. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyo-fillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions: the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol. 2009;53:919-928.
8. Vignali L, Saia F, Manari A, Santarelli A, Rubboli A, Varani E, Pio-vaccari G, Menozzi A, Percoco G, Benassi A, Rusticali G, Marzaroli P, Guastaroba P, Grilli R, Maresta A, Marzocchi A. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the Registro Regionale Angio-pLastiche Emilia-Romagna registry). Am J Cardiol. 2008;101:947-952.
9. Moses JW, Stone GW, Nikolsky E, Mintz GS, Dangas G, Grube E, Ellis SG, Lansky AJ, Weisz G, Fahy M, Na Y, Russell ME, Donohoe D, Leon MB, Mehran R. Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. J Am Coll Cardiol. 2006;47:2164-2171.
10. Sousa JE, Costa MA, Tuzcu EM, Yadav JS, Ellis S. New frontiers in interventional cardiology. Circulation. 2005;111:671-681.
11. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772-1778. (Pubitemid 37296082)
12. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664-1672. (Pubitemid 37243650)
13. Costa MA, Gigliotti OS, Zenni MM, Gilmore PS, Bass TA. Synergistic use of sirolimus-eluting stents and intravascular ultrasound for the treatment of unprotected left main and vein graft disease. Catheter Car-diovasc Interv. 2004;61:368-375.
14. Ramcharitar S, Gonzalo N, van Geuns RJ, Garcia-Garcia HM, Wykr-zykowska JJ, Ligthart JM, Regar E, Serruys PW. First case of stenting of a vulnerable plaque in the SECRITT I trial: the dawn of a new era? Nat Rev Cardiol. 2009;6:374-378.
15. Schepers A, Eefting D, Bonta PI, Grimbergen JM, de Vries MR, van Weel V, de Vries CJ, Egashira K, van Bockel JH, Quax PH. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2006;26:2063-2069.
16. Payeli SK, Latini R, Gebhard C. Prothrombotic gene expression profile in vascular smooth muscle cells of human saphenous vein, but not internal mammary artery. Arterioscler Thromb Vasc Biol. 2008;28:705-710.